Cargando…

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells

Systemic mastocytosis (SM) is a mast cell (MC) neoplasm with complex pathology and a variable clinical course. In aggressive SM (ASM) and MC leukemia (MCL) responses to conventional drugs are poor and the prognosis is dismal. R763 is a multi-kinase inhibitor that blocks the activity of Aurora-kinase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peter, Barbara, Bibi, Siham, Eisenwort, Gregor, Wingelhofer, Bettina, Berger, Daniela, Stefanzl, Gabriele, Blatt, Katharina, Herrmann, Harald, Hadzijusufovic, Emir, Hoermann, Gregor, Hoffmann, Thomas, Schwaab, Juliana, Jawhar, Mohamad, Willmann, Michael, Sperr, Wolfgang R., Zuber, Johannes, Sotlar, Karl, Horny, Hans-Peter, Moriggl, Richard, Reiter, Andreas, Arock, Michel, Valent, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037300/ https://www.ncbi.nlm.nih.gov/pubmed/29249817 http://dx.doi.org/10.1038/leu.2017.338

Ejemplares similares

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2019)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

Engraftment in NSG(SCF) mice correlates with the WHO category and prognosis in systemic mastocytosis
por: Willmann, Michael, et al.
Publicado: (2023)

In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells
por: Gamperl, Susanne, et al.
Publicado: (2020)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal
por: Willmann, Michael, et al.
Publicado: (2021)

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma
por: Blatt, Katharina, et al.
Publicado: (2016)

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
por: Stefanzl, Gabriele, et al.
Publicado: (2017)

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
por: Valent, Peter, et al.
Publicado: (2019)

Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells
por: Gamperl, Susanne, et al.
Publicado: (2019)

Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms
por: Willmann, Michael, et al.
Publicado: (2018)

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph(+) chronic myeloid leukemia
por: Peter, Barbara, et al.
Publicado: (2022)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes
por: Valent, Peter, et al.
Publicado: (2022)

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
por: Valent, Peter, et al.
Publicado: (2018)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils
por: Blatt, Katharina, et al.
Publicado: (2012)

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia
por: Gleixner, Karoline V., et al.
Publicado: (2017)

The underestimated role of basophils in Ph(+) chronic myeloid leukaemia
por: Valent, Peter, et al.
Publicado: (2018)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population
por: Graf, Irene, et al.
Publicado: (2022)

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
por: Hadzijusufovic, Emir, et al.
Publicado: (2017)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
por: Nedoszytko, Boguslaw, et al.
Publicado: (2021)

Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph(+) Chronic Myeloid Leukemia
por: Sadovnik, Irina, et al.
Publicado: (2022)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2021)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm
por: Jawhar, Mohamad, et al.
Publicado: (2017)

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal()
por: Valent, Peter, et al.
Publicado: (2017)

Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts
por: Valent, Peter, et al.
Publicado: (2020)

STAT5 is Expressed in CD34(+)/CD38(−) Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms
por: Hadzijusufovic, Emir, et al.
Publicado: (2020)

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
por: Hoermann, Gregor, et al.
Publicado: (2015)

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
por: Valent, Peter, et al.
Publicado: (2020)

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
por: Herrmann, Harald, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fhtbce7jbprfa9rk1haucgoc0s